Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71

Medtronic plc

Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.
Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.
Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.
FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty.

item 2.02item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Skip Kiil

EVP and President, Cardiovascular Portfolio

MDT · Medtronic plc

Effective: 2025-05-21
Filed: May 21, 2025 23:59 UTC

Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio

Departed

Sean Salmon

EVP and President, Cardiovascular Portfolio

MDT · Medtronic plc

Effective: 2025-05-21
Successor: Skip Kiil
Filed: May 21, 2025 23:59 UTC

Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio

Source: SEC EDGAR

accession 0001613103-25-000078

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.